Ken Griffin Standard Biotools Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.42 - $2.35 $20,448 - $33,840	14,400 Added 112.5%	27,200 $52,000
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.92 $63,231 - $111,900	-38,322 Reduced 74.96%	12,800 $22,000
Q1 2024 May 15, 2024	BUY	$1.87 - $2.78 $89,053 - $132,389	47,622 Added 1360.63%	51,122 $138,000
Q4 2023 Feb 14, 2024	SELL	$1.59 - $2.73 $10,812 - $18,564	-6,800 Reduced 66.02%	3,500 $7,000
Q3 2023 Nov 14, 2023	BUY	$1.9 - $3.05 $14,630 - $23,485	7,700 Added 296.15%	10,300 $29,000
Q2 2023 Aug 14, 2023	SELL	$1.47 - $2.56 $1,617 - $2,816	-1,100 Reduced 29.73%	2,600 $5,000
Q1 2023 May 15, 2023	SELL	$1.3 - $2.24 $17,940 - $30,912	-13,800 Reduced 78.86%	3,700 $7,000
Q4 2022 Feb 14, 2023	BUY	$0.93 - $1.52 $5,673 - $9,272	6,100 Added 53.51%	17,500 $20,000
Q3 2022 Nov 14, 2022	SELL	$1.1 - $2.06 $9,020 - $16,892	-8,200 Reduced 41.84%	11,400 $13,000

142

279M

27.2K

34.1K

Ticker LAB
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 78,654,800
Market Cap $144M
Description
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.